




RealRate

PHARMACEUTICAL 2013

Tenax Therapeutics INC
Rank 196 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tenax Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tenax Therapeutics INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 3.4% points. The greatest weakness of Tenax Therapeutics INC is the variable Assets, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 176% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	2,631
Cost of Goods Sold	0
Intangible Assets	873
Liabilities, Current	3,127
Liabilities, Non-Current	0
Other Assets	344
Other Compr. Net Income	0
Other Expenses	7,442
Other Liabilities	1,361
Other Net Income	-80
Other Revenues	364
Property and Equipment	294
Research and Development	2,463
Selling, General and Administrative Expense	6,092

Output Variable	Value in 1000 USD
Assets	4,142
Liabilities	4,488
Expenses	15,996
Revenues	364
Stockholders Equity	-346
Net Income	-15,712
Comprehensive Net Income	-15,712
BaseVar	12,535
ECR before LimitedLiability	-382%
Economic Capital Ratio	44%